Immune-based therapies in penile cancer

Joshi, Vidhu; Spiess, Philippe E.; Necchi, Andrea; Pettaway, Curtis A.; Chahoud, Jad

doi:10.1038/s41585-022-00617-x

Cited by 28 publications

(18 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A high level of CD163 + TAMs (M2) was found to be associated with worse prognosis and higher tumor stage in NSCLC ( 95 ), whereas in penile cancer, a high level of CD163 + TAMs was associated with increased LNM rather than poor survival ( 68 ). The high plasticity of TAMs and the limitation of using CD markers alone to differentiate TAMs may contribute to the contradictory phenomenon shown in penile cancer with traditionally thought of the role of TAMs ( 36 ).…”

Section: Tumor Immune Microenvironmentmentioning

confidence: 99%

“…However, the few and mainly case reports and basket trial data on the effect of pembrolizumab on clinical outcomes limited its widespread use in lethal advanced PSCC ( 31 – 34 ). Just as higher expression of PDL1 correlates with improved response to ICI in other tumors ( 35 ), the high PDL1 expression rate in PSCC tissue suggests that ICI may be a potentially effective treatment for PSCC ( 36 ). In addition, the distinct molecular mechanisms and prognosis between HPV-positive and HPV-negative PSCC make HPV-related therapies, such as therapeutic HPV vaccines, a potential focus for penile cancer treatment ( 37 , 38 ).…”

Section: Introductionmentioning

confidence: 99%

“…In addition, the distinct molecular mechanisms and prognosis between HPV-positive and HPV-negative PSCC make HPV-related therapies, such as therapeutic HPV vaccines, a potential focus for penile cancer treatment ( 37 , 38 ). Moreover, adoptive T cells therapy (ATC) has also shown efficacy in treating advanced penile cancer in some early clinical trials, also emerging as a potential treatment for penile cancer ( 36 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immune landscape and immunotherapy for penile cancer

Tang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Penile cancer is a rare malignancy and usually refers to penile squamous cell carcinoma (PSCC), which accounts for more than 95% of all penile malignancies. Although organ-sparing surgery is an effective treatment for early-stage PSCC, surgical intervention alone is often not curative for advanced PSCC with metastases to the inguinal and/or pelvic lymph nodes; thus, systemic therapy is required (usually platinum-based chemotherapy and surgery combined). However, chemotherapy for PSCC has proven to be of limited efficacy and is often accompanied by high toxicity, and patients with advanced PSCC usually have poor prognosis. The limited treatment options and poor prognosis indicate the unmet need for advanced PSCC. Immune-based therapies have been approved for a variety of genitourinary and squamous cell carcinomas but are rarely reported in PSCC. To date, several studies have reported high expression of PDL1 in PSCC, supporting the potential application of immune checkpoint inhibitors in PSCC. In addition, human papillomavirus (HPV) infection is highly prevalent in PSCC and plays a key role in the carcinogenesis of HPV-positive PSCC, suggesting that therapeutic HPV vaccine may also be a potential treatment modality. Moreover, adoptive T cell therapy (ATC) has also shown efficacy in treating advanced penile cancer in some early clinical trials. The development of new therapeutics relies on understanding the underlying biological mechanisms and processes of tumor initiation, progression and metastasis. Therefore, based on the interest, we reviewed the tumor immune microenvironment and the emerging immunotherapy for penile cancer.

show abstract

Section: Tumor Immune Microenvironmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immune landscape and immunotherapy for penile cancer

Tang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…At present, systemic therapy options have been limited to common chemotherapies (eg, cisplatin, paclitaxel, ifosfamide, and docetaxel), and when tumors are refractory to combination systemic therapy (eg, paclitaxel, ifosfamide, and cisplatin), the median survival is poor with no effective therapies. Targeted monoclonal antibody–based therapies (eg, cetuximab and panitumumab) and various immune checkpoint inhibitors are being assessed either alone or in combination with other agents, although mostly in the setting of grouped histology basket trials [2] , [3] . Recently, promising tumor control was described in 17 patients with stage IV PSCC treated with combined platinum-based chemotherapy, epidermal growth factor receptor blockade, and anti–programmed death receptor-1 (anti–PD-1) antibody [4] .…”

mentioning

confidence: 99%

An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma

Grass¹,

Chahoud²,

Lopez³

et al. 2023

European Urology Open Science

Self Cite

View full text Add to dashboard Cite

“…Additionally, these cells stimulate the host immune response by releasing cytokines, cytokine receptors, and other factors, which directly or indirectly promote or alternatively inhibit tumor cell proliferation ( 9 , 10 ). Collectively these processes direct key events such as tumor recurrence, metastasis, and response to the immunotherapy ( 11 , 12 ), thereby influencing clinical outcomes ( 13 – 15 ). However, the detailed profiles of immune cell infiltration and differentially expressed genes (metabolic, immune-related, or others) in many cancers continue to be elucidated ( 7 , 16 , 17 ).…”

mentioning

confidence: 99%

Editorial: Complexity of tumor microenvironment: A major culprit in cancer development

et al. 2022

View full text Add to dashboard Cite

The tumor microenvironment (TME) is a complex landscape composed of intrinsic and extrinsic elements besides tumor cells including various immune cells, tumor-related stromal cells, and endothelial cells along with extracellular matrix components (1-3). Notably, the ability of tumor cells to invade surrounding tissues or metastasize through blood and lymphatic vessels implicitly involves cooperation with elements of the TME (4-6). In this regard, infiltrating immune cells such as T cells, B cells, macrophages, dendritic cells, monocytes, neutrophils, and mast cells have been associated with cancer development and progression (6-8). Additionally, these cells stimulate the host immune response by releasing cytokines, cytokine receptors, and other factors, which directly or indirectly promote or alternatively inhibit tumor cell proliferation (9, 10). Collectively these processes direct key events such as tumor recurrence, metastasis, and response to the immunotherapy (11, 12), thereby influencing clinical outcomes (13-15). However, the detailed profiles of immune cell infiltration and differentially expressed genes (metabolic, immune-related, or others) in many cancers continue to be elucidated (7,16,17). Several metabolic factors have shown an association with pathogenesis and progression of various cancers (18, 19) such as de novo lipid biosynthesis is a crucial regulator in the prostate cancer (20)(21)(22). An anecdotal observation metabolic health of the individuals may influence the prognosis and treatment of the cancers.Indeed, support for this intriguing hypothesis is gaining momentum, for example, androgen deprivation therapy (ADT) reduces testosterone in the body which inhibits the prostate cancer (23-25). However, studying constituents of the TME can help understand Frontiers in Endocrinology frontiersin.org 01

show abstract

Immune-based therapies in penile cancer

Cited by 28 publications

References 200 publications

Immune landscape and immunotherapy for penile cancer

Immune landscape and immunotherapy for penile cancer

An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma

Editorial: Complexity of tumor microenvironment: A major culprit in cancer development

Contact Info

Product

Resources

About